GlassScriptPhysician profile
Bruce Franklin Schilt
NPI 1154320893
$6,545.73
in general payments reported to CMS, 2019-2025
33 companies · $624 in 2025
The $624 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,412 · 2020: $219 · 2021: $850 · 2022: $979 · 2023: $1,385 · 2024: $1,076 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,084.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $977.77 | 2019-2025 | Confirm Rx, Dragonfly Opstar, Assurity |
| Astrazeneca Pharmaceuticals LP | $712.11 | 2019-2024 | Wainua, Brilinta, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $648.67 | 2021-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $412.88 | 2019-2024 | Rotapro, Watchman Flx |
| Amgen INC. | $404.41 | 2019-2025 | Repatha, Repatha |
| Biotronik INC. | $357.17 | 2022-2024 | Orsiro Mission, Pk Papyrus |
| Novartis Pharmaceuticals Corporation | $347.06 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $313.67 | 2019-2025 | Jardiance |
| Pfizer INC. | $289.00 | 2019-2025 | |
| Shockwave Medical, INC | $284.96 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amarin Pharma, INC. | $254.40 | 2019 | |
| Janssen Pharmaceuticals, INC | $220.16 | 2019-2023 | Xarelto |
| Edwards Lifesciences Corporation | $210.90 | 2022-2023 | Sapien 3 Ultra Resilia |
| Chiesi USA, INC. | $183.12 | 2019-2024 | Kengreal, Cleviprex |
| Medtronic, INC. | $165.21 | 2021-2024 | Mvp, Onyx Frontier |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $152.51 | 2025 | Ozempic |
| Abiomed | $142.28 | 2023 | Impella |
| Philips North America LLC | $135.40 | 2019-2020 | |
| Vifor Pharma, INC. | $56.09 | 2019 | |
| Sanofi-Aventis U.S. LLC | $47.13 | 2019 | |
| Terumo Medical Corporation | $25.85 | 2019 | |
| Gilead Sciences, INC. | $24.70 | 2019 | |
| Kestra Medical Technology Services, INC. | $23.53 | 2024 | Assure Wcd |
| Esperion Therapeutics, INC. | $19.43 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.96 | 2025 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $18.44 | 2023 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $17.65 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $15.54 | 2024 | Arcalyst |
| Daiichi Sankyo INC. | $14.69 | 2019 | |
| Astellas Pharma US INC | $14.16 | 2019 | |
| Merck Sharp & Dohme LLC | $13.40 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $12.27 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Schilt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.